Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Personalis, Inc. - Common Stock (NQ:PSNL)

9.095 -0.175 (-1.89%)
Streaming Delayed Price Updated: 1:16 PM EST, Dec 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Personalis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Personalis to Participate at the 22nd Annual Needham Virtual Healthcare Conference
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Joins Top UK Cancer Research Organizations to Evaluate Earlier Cancer Recurrence Detection Through Groundbreaking Study
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay
From Personalis, Inc.
Via Business Wire
News headline image
Personalis's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Earnings Outlook For Personalis ↗
 
Via Benzinga
News headline image
Personalis Appoints Christopher Hall as Chief Executive Officer
From Personalis, Inc.
Via Business Wire
News headline image
Toll Brothers To Rally 25%? Here Are 10 Other Analyst Forecasts For Friday ↗
Oppenheimer boosted the price target for Universal Display Corporation (NASDAQ: OLED) from $150 to $160. Oppenheimer analyst Martin Yang maintained an Outperform rating on the stock. Universal Display... 
Via Benzinga
News headline image
Personalis Reports Fourth Quarter and Full Year 2022 Financial Results
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Announce Fourth Quarter and Full Year 2022 Financial Results
From Personalis, Inc.
Via Business Wire
News headline image
Cancer Genomics-Focused Personalis To Reduce Nearly One-Third Of Its Workforce ↗
 
Via Benzinga
News headline image
Personalis's Return On Capital Employed Overview ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 23, 2023 ↗
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Personalis to Participate at Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
News headline image
Analyst Upgrades Personalis; Says Biopharma Is Strong, Cash Burn Is Down ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 6, 2023 ↗
 
Via Benzinga
News headline image
Why Personalis Shares Are Trading Higher Today ↗
 
Via Benzinga
News headline image
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue
From Personalis, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  Thursday's session saw 329 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 152 stocks made new 52-week lows. 
Via Benzinga
News headline image
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Announces CEO Retirement and Transition
From Personalis, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  On Tuesday, 298 companies achieved new lows for the year. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Present at the 34th Annual Piper Sandler Healthcare Conference
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Reports Third Quarter 2022 Financial Results
From Personalis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.